Zopiclone 7.5 mg remains a useful pharmacological option for the short‑term treatment of insomnia in carefully selected adult patients. When prescribed judiciously, at the lowest effective dose and for the shortest necessary duration, it can provide meaningful symptomatic relief. However, its use is accompanied by important safety considerations, including the risk of dependence, cognitive impairment, and complex sleep behaviors. Clinicians must balance potential benefits against known risks, emphasize non‑pharmacological therapies, and engage patients through education and shared decision‑making. By integrating zopiclone into a comprehensive, patient‑centered insomnia management strategy, healthcare professionals can optimize outcomes while minimizing harm.